Common Pain Mechanisms in Migraine, Migraine-Related Neck Pain, and Lower Back Pain: A Cross Sectional Study

May 16, 2026 updated by: Dilara Onan, Bozok University

From Mechanisms to Clinical Evidence: A Cross-Sectional Study of Common Pain Mechanisms in Migraine, Migraine-Related Neck Pain, and Lower Back Pain

Migraine is one of the primary headache disorders with a high prevalence worldwide, leading to significant disability and reduced quality of life. Trigeminal nerve activation and alterations in central pain processing mechanisms play a crucial role in the pathophysiology of migraine. Recent studies suggest that migraine may not only be a headache disorder but also a systemic pain disorder associated with changes in central pain processing mechanisms. Central sensitization is defined as increased sensitivity of nociceptive neurons in the central nervous system to afferent stimuli and is considered a key mechanism in the development and maintenance of chronic pain conditions. This condition is characterized by pain hypersensitivity, allodynia, and generalized pain sensitivity.

In addition to headaches, other musculoskeletal pains are also frequently reported in migraine patients. Spinal pain, particularly neck and lower back pain, can occur in migraine sufferers, with central sensitization contributing to the condition, considering the spine as a chain. Large population-based studies have shown a significant association between primary headaches and persistent low back pain, and a higher prevalence of concomitant low back pain has been reported in individuals with chronic migraine and chronic tension-type headaches. This association is suggested to be explained by the shared nociceptive pathways of the head and spinal structures and the changes in central pain processing seen in chronic pain conditions.

This relationship between migraine and musculoskeletal pain is also explained by the presence of shared neuroanatomical structures such as the trigemino-cervical complex. Nociceptive afferents from the upper cervical spine and cranial structures converge at the trigemino-cervical complex level in the brainstem, creating a predisposition to the co-occurrence of head and neck pain. This mechanism suggests that pain or dysfunction in the cervical region in migraine patients may be related to headache symptoms. Studies have shown that neck pain is more common in individuals with migraine than in the general population, and research suggests this rate may be approximately 10-12 times higher compared to healthy individuals. Furthermore, it has been reported that individuals with migraine more frequently experience tenderness in cranio-cervical muscles such as the upper trapezius, sternocleidomastoid, and suboccipital muscles, myofascial trigger points, and increased muscle sensitivity. The literature also emphasizes that these cervical symptoms may be related to migraine frequency, attack severity, and headache-related disability.

These findings suggest that migraine should be considered not only as a primary headache disorder but also as a complex neurobiological condition associated with widespread pain sensitivity and musculoskeletal symptoms. A better understanding of the relationship between migraine and musculoskeletal pain could be important for developing multidisciplinary treatment approaches. However, clinical studies in the literature that evaluate migraine, accompanying neck pain, and lower back pain together in terms of common pain mechanisms are quite limited. Therefore, the rationale for this study is that examining factors such as central sensitization, pain threshold, pain catastrophizing, psychological factors, body awareness, and regional disability together in migraine patients can lead to a better understanding of the pathophysiology of migraine-related musculoskeletal pain. Based on all these reasons and evidence, the aim of this study is to investigate the possible common pain mechanisms and musculoskeletal pathophysiological processes of migraine-related neck and back pain in migraine patients with accompanying neck and/or back pain by evaluating factors such as central sensitization, pain threshold, pain catastrophizing, psychological factors, body awareness, and regional disability together.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

179

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Gaziantep City Hospital, Department of Neurology, Gaziantep, Türkiye.

Description

Inclusion Criteria:

  • Being between 18 and 65 years of age,
  • Being able to read and understand Turkish,
  • Agreeing to participate voluntarily,
  • Having an episodic or chronic migraine diagnosis according to the International Classification of Headache Disorders Edition 3 criteria;
  • Having neck pain and/or lower back pain without any underlying diagnosis accompanying the migraine diagnosis.

Exclusion Criteria:

  • A history of neurological disorder (e.g., Multiple Sclerosis),
  • Inflammatory rheumatic disorders (e.g., Rheumatoid Arthritis), generalized chronic pain syndromes (e.g., Fibromyalgia),
  • Any other headache disease, any other systemic disease,
  • Acute fracture and infection,
  • Spinal surgery or spinal disease diagnosis within the last 6 months,
  • Serious musculoskeletal trauma within the last 6 months,
  • Pregnancy,
  • A cognitive or psychiatric condition that would prevent completion of the questionnaires,
  • In the control group without a migraine diagnosis,
  • A history of recurrent headaches within the last year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Episodic migraine
Episodic migraine is a neurological condition characterized by recurrent, moderate-to-severe headaches occurring on fewer than 15 days per month. Attacks typically last 4 to 72 hours and are often accompanied by nausea, vomiting, and light/sound sensitivity. Treatment involves acute, on-demand medication and preventative strategies to reduce attack frequency.
Chronic migraine
Chronic migraine is defined by having 15 or more headache days per month for over three months, with at least eight of those days meeting migraine criteria. Symptoms include moderate-to-severe throbbing pain, nausea, vomiting, and extreme sensitivity to light, sound, or smell.
Episodic migraine with neck pain
Episodic migraine is a neurological condition characterized by recurrent, moderate-to-severe headaches occurring on fewer than 15 days per month. Attacks typically last 4 to 72 hours and are often accompanied by nausea, vomiting, and light/sound sensitivity. Treatment involves acute, on-demand medication and preventative strategies to reduce attack frequency. Additionally, this sample includes individuals diagnosed with episodic migraine and experiencing neck pain without having any other diagnosed neck problems.
Episodic migraine with low back pain
Episodic migraine is a neurological condition characterized by recurrent, moderate-to-severe headaches occurring on fewer than 15 days per month. Attacks typically last 4 to 72 hours and are often accompanied by nausea, vomiting, and light/sound sensitivity. Treatment involves acute, on-demand medication and preventative strategies to reduce attack frequency. Additionally, this sample includes individuals diagnosed with episodic migraine and experiencing low back pain without having any other diagnosed lower back problems.
Episodic migraine with neck pain and low back pain
Episodic migraine is a neurological condition characterized by recurrent, moderate-to-severe headaches occurring on fewer than 15 days per month. Attacks typically last 4 to 72 hours and are often accompanied by nausea, vomiting, and light/sound sensitivity. Treatment involves acute, on-demand medication and preventative strategies to reduce attack frequency. Additionally, this sample includes individuals diagnosed with episodic migraine and experiencing neck pain and low back pain without having any other diagnosed neck and lower back problems.
Chronic migraine with neck pain
Chronic migraine is defined by having 15 or more headache days per month for over three months, with at least eight of those days meeting migraine criteria. Symptoms include moderate-to-severe throbbing pain, nausea, vomiting, and extreme sensitivity to light, sound, or smell. Additionally, this sample includes individuals diagnosed with chronic migraine and experiencing neck pain without having any other diagnosed neck problems.
Chronic migraine with low back pain
Chronic migraine is defined by having 15 or more headache days per month for over three months, with at least eight of those days meeting migraine criteria. Symptoms include moderate-to-severe throbbing pain, nausea, vomiting, and extreme sensitivity to light, sound, or smell. Additionally, this sample includes individuals diagnosed with chronic migraine and experiencing low back pain without having any other diagnosed lower back problems.
Chronic migraine with neck pain and low back pain
Chronic migraine is defined by having 15 or more headache days per month for over three months, with at least eight of those days meeting migraine criteria. Symptoms include moderate-to-severe throbbing pain, nausea, vomiting, and extreme sensitivity to light, sound, or smell. Additionally, this sample includes individuals diagnosed with chronic migraine and experiencing neck pain and low back pain without having any other diagnosed neck and lower back problems.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Central Sensitization Inventory
Time Frame: Day 1
The Central Sensitization Inventory (CSI) measures somatic and emotional symptoms common in central sensitization syndrome. Section A measures 25 symptoms with 5 response options (0 to 4). The total score ranges from 0 to 100. Section B asks patients whether they have previously been diagnosed with preliminary specific CSI conditions.
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Headache Intensity
Time Frame: Day 1
The Numerical Pain Rating Scale (NPRS) consists of pain levels where the person indicates the pain they are currently experiencing with a vertical line on a plane. The pain felt by the person is given on a scale of 0-10, "0: no pain", "10: I feel very severe pain".
Day 1
Headache Impact
Time Frame: Day 1
The Headache Impact Test-6 (HIT-6) is a questionnaire for headaches that assesses vitality, pain, psychological distress, sociability, role, and cognitive functioning. Each item is scored on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, 13=always). The total score is determined by summing the scores on all six items and ranges from 36 to 78 points. (≤49 = little/no impact, 50-55 = some impact, 56-59 = significant impact, and 60-78 = serious impact).
Day 1
Disability for Migraine
Time Frame: Day 1
The Migraine Disability Assessment (MIDAS) questionnaire evaluates the last 3 months of disability and consists of a 5-item self-administered test covering disability at work/school, household chores, family and social or leisure activities. The total number of days missed in these activities is the total score and classifies the disability as minimal disability (0-5 points), mild disability (6-10 points), moderate disability (11-20 points), or severe disability (≥21).
Day 1
Disability of the Neck
Time Frame: Day 1
The Neck Disability Index includes a total of 10 questions covering topics such as pain, personal care, concentration, work, driving, and sleeping. Each question is scored on a scale of 0 to 5 points. The questionnaire is graded out of a maximum of 50 points. A score of "0" means no limitations, while a score of "50" means a complete disability.
Day 1
Disability of the Lower Back
Time Frame: Day 1
The Oswestry Disability Index consists of 10 questions that assess the extent to which back pain affects various daily living activities such as sitting, personal care (dressing, bathing, etc.), standing, walking, sleeping, and traveling. Each question is scored on a scale of 0-5, with a total score of 0-100. Higher scores indicate a higher level of functional disability.
Day 1
Pain Catastrophizing
Time Frame: Day 1
The Pain Catastrophizing Scale is a 13-item scale that assesses negative thoughts and feelings related to experienced pain. Each item is scored between 0-never and 4-always. The total score ranges from 0-52, with higher scores indicating a higher level of pain catastrophizing. The scale consists of subscales of "Helplessness, Magnification, and Rumination."
Day 1
Anxiety and Depression
Time Frame: Day 1
The Hospital Anxiety and Depression Scale (HADS) consists of 14 items; 7 items assess anxiety symptoms and 7 items assess depression symptoms. Each item is scored between 0 and 3 points. By summing the subscale scores, a score of 0-21 can be obtained for each of the Depression and Anxiety subscales. For each subscale, a score of 0-7 is considered the normal range, a score of 8-10 suggests the presence of a mood disorder, and a score of 11 or higher indicates a possible mood disorder.
Day 1
Headache Awareness
Time Frame: Day 1
The Fremantle Headache Awareness Questionnaire (FHAQ) is a Likert-type questionnaire (0=Never/Never feel like this, 1=Rarely feel like this, 2=Sometimes or occasionally feel like this, 3=Frequently feel like this, 4=Always or most of the time) that assesses altered perceptions related to headache in an individual. The questionnaire asks individuals nine questions, including how they perceive their head relative to their body and how they perceive their body position when experiencing a headache.
Day 1
Neck Awareness
Time Frame: Day 1
The Fremantle Neck Awareness Questionnaire (FreNAQ) is a Likert-type questionnaire (0=Never/Never feel like this, 1=Rarely feel like this, 2=Sometimes or occasionally feel like this, 3=Frequently feel like this, 4=Always or most of the time) that assesses an individual's perception of altered neck-specific sensations. The questionnaire asks nine questions, including how individuals perceive their neck relative to their body and how they perceive their body position.
Day 1
Back Awareness
Time Frame: Day 1
The Fremantle Back Awareness Questionnaire (FBAQ) is a Likert-type questionnaire (0=Never/Never feel like this, 1=Rarely feel like this, 2=Sometimes, or occasionally feel like this, 3=Frequently feel like this, 4=Always or most of the time) that assesses an individual's altered perception of their waist. The questionnaire asks individuals nine questions, including how they perceive their waist relative to their body and how they perceive their body position.
Day 1
Pressure Pain Threshold Assessment
Time Frame: Day 1
Pressure pain threshold measurements will be performed using an analog algometer to objectively assess pain sensitivity. The pressure pain threshold is defined as the pressure value at which an individual first reports a sensation of pain during mechanical pressure application, and it is a reliable and widely used method in the assessment of musculoskeletal pain and central sensitization. Measurements will be performed bilaterally over the temporalis muscle, superior trapezius muscle, suboccipital muscles, and lumbar paraspinal muscles to assess migraine-related pain sensitivity and possible generalized sensitivity. The analog algometer probe will be placed perpendicular to the measurement point, and the pressure will be increased gradually. Participants will be asked to report their first sensation of pain, and the value at this point will be recorded. Three repetitions will be performed for each measurement point, and the average value will be used in the analyses.
Day 1
Allodynia
Time Frame: Day 1
The "Allodynia Symptom Checklist (ASC-12)" is a 12-item questionnaire where zero points are awarded for "Not applicable to me," "Never," and "Rarely," one point for "Less than half," and two points for "More than half." Total scores range from "0" to "24." Allodynia levels are determined as follows: 0-2 points: none, 3-5 points: mild, 6-8 points: moderate, 9 and above: severe.
Day 1
Demographic and Clinic Evaluations
Time Frame: Day 1
Demographic and clinical information such as sex, age, weight, height, education level, occupation, medical history, family history, number of years diagnosed with migraine (if any), migraine triggers, symptoms experienced during attacks, number of headache days per month, number of headache attacks per month, duration of attacks, and localization of headaches will be recorded for all patients.
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bozok University

Investigators

  • Principal Investigator: Dilara Onan, PhD, Yozgat Bozok University
  • Study Chair: Merve Ceren Akgör, Neurologist, Department of Neurology, University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Türkiye
  • Study Chair: Doğan Porsnok, PhD, Bingol University
  • Study Chair: Pelin Yenilmez Yeşildaş, Neurologist, Gaziantep City Hospital, Department of Neurology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 30, 2026

Primary Completion (Estimated)

June 17, 2026

Study Completion (Estimated)

June 30, 2026

Study Registration Dates

First Submitted

April 22, 2026

First Submitted That Met QC Criteria

May 4, 2026

First Posted (Actual)

May 5, 2026

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 16, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Approval No: 3/9; 02.04.2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Back Pain

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe